The Optical Remote Monitoring Blood Pressure Revolution ...at Your Fingertip.
We're on a mission to make democratized blood pressure management via instant, ubiquitous, and accurate remote monitoring a reality. With a touch of the finger, the Biospectal OptiBP™ platform allows anyone to transform mobile devices into a medical grade blood pressure monitoring solution wherever and whenever it's needed...
We're in the running for the #1 Swiss startup! Please vote for us and help us fight the global blood pressure epidemic and improve the lives of millions.
We are working relentlessly to democratize blood pressure management at global scale using breakthrough transdermal optical biosensing in mobile devices. It’s a privilege to be recognized for our vision, passion, and progress as one of the top three Swiss Medtech Award 2022 Finalists. The winner of the prestigious award and cash prize will be announced at Swiss Medtech Day on June 14 in Bern, Switzerland
For more on the Swiss Medtech 2022 Award and finalists, read here.
SXSW 2022 has selected Biospectal to join its list of Innovation Award finalists from a huge number of entries for the award ceremony in Austin, TX on 14 March. Come talk with us about our fingertip optical sensing with OptiBP and Biodisc on Saturday at the Innovator’s showcase!
All-in-one blood pressure monitoring device, Biodisc democratizes access and expands the reach of Biospectal’s blood pressure monitoring platform from smartphones and other connected mobile devices, to clinics, hospitals, work and home The Biospectal team is excited to announce the debut of Biodisc™, a stand-alone, sleekly-designed, all-in-one, blood pressure monitoring device at CES 2022. Biospectal also plans to announce the public beta launch of Biospectal OptiBP™ for iOS at CES 2022,
LAUSANNE, SWITZERLAND – NOVEMBER 18, 2021 – Biospectal SA, the remote patient monitoring biosensing software company, today announced the Biospectal OptiBP™ smartphone blood pressure monitoring app and data platform has been named a winner in the Health category for Fast Company’s Next Big Things in Tech list, honoring the technology breakthroughs that promise to shape the future of their industries — from healthcare to agriculture to artificial intelligence and more.
Today we are happy to announce the closing of a CHF 4.0M($4.3M) round of seed funding led by digital health investor, SeedLink, with additional funding from LabCorp, Athensmed, Swiss based Privilege Ventures and other European and US investors. Biospectal will leverage the new funds to scale its OptiBP™ smartphone blood pressure monitoring application and data platform technology worldwide. The funding we’ve received will accelerate Biospectal’s growth trajectory along with the
We’re proud to announce two independent global research and validation studies which integrate the Biospectal OptiBP™ blood pressure measurement app. Currently underway in four low-resource countries, the studies center on the routine measurement and monitoring of blood pressure, assessment of hypertension during pregnancy, and enable global field testing and validation of Biospectal’s OptiBP smartphone app and data platform integration with the WHO’s Digital Antenatal Care module, following WHO SMART guidelines
We’re excited to announce Biospectal has been chosen as one of 10 companies selected to represent Switzerland on the global stage at MWC Barcelona (June 28–July 1, 2021). We look forward to attending and meeting with top-notch investors and industry leaders at several of MWC’s key events, such as the 4YFN startup conference. Selected from nearly 100 applications, the companies chosen for Venture Leaders Mobile 2021 represent and highlight Switzerland’s